Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.75% |
| 2 | Technology | 13.74% |
| 3 | Healthcare | 12.69% |
| 4 | Industrials | 11.51% |
| 5 | Consumer Discretionary | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALSK
2026
DELISTED
Alaska Communications Systems
ALSK
| $2.86M | ﹤0.01% |
1,745,160
+205,720
| +13% | +$336K |
|
2027
CrossAmerica Partners
CAPL
$900M
| $2.85M | ﹤0.01% |
113,337
-9,663
| -8% | -$249K |
|
2028
EPAM Systems
EPAM
$5.18B
| $2.85M | ﹤0.01% |
+44,400
| New | +$2.85M |
|
2029
Church & Dwight Co
CHD
$24B
| $2.85M | ﹤0.01% |
64,400
-356,900
| -85% | -$16.3M |
|
|
GDEN
2030
DELISTED
Golden Entertainment
GDEN
| $2.85M | ﹤0.01% |
234,950
-22,050
| -9% | -$266K |
|
2031
Baxter International
BAX
$13.8B
| $2.84M | ﹤0.01% |
64,100
-93,900
| -59% | -$4.34M |
|
2032
H&R Block
HRB
$6.83B
| $2.83M | ﹤0.01% |
123,088
-693,312
| -85% | -$15.9M |
|
2033
Nice
NICE
$5.99B
| $2.83M | ﹤0.01% |
41,144
-34,500
| -46% | -$2.3M |
|
|
NOA
2034
North American Construction
NOA
$375M
| $2.82M | ﹤0.01% |
733,260
+144,217
| +24% | +$481K |
|
|
SNCR
2035
DELISTED
Synchronoss Technologies
SNCR
| $2.82M | ﹤0.01% |
8,189
+5,933
| +263% | +$2.23M |
|
2036
First Financial Bankshares
FFIN
$5.06B
| $2.82M | ﹤0.01% |
124,800
-172,800
| -58% | -$3.55M |
|
|
EVA
2037
DELISTED
Enviva Inc.
EVA
| $2.82M | ﹤0.01% |
105,200
-46,200
| -31% | -$1.25M |
|
2038
Diana Shipping
DSX
$309M
| $2.82M | ﹤0.01% |
1,333,778
+113,711
| +9% | +$233K |
|
|
ADVM
2039
DELISTED
Adverum Biotechnologies
ADVM
| $2.81M | ﹤0.01% |
96,970
-3,470
| -3% | -$113K |
|
|
CBPX
2040
DELISTED
CONTINENTAL BUILDING PRODUCTS, INC.
CBPX
| $2.81M | ﹤0.01% |
121,700
-97,800
| -45% | -$2.12M |
|
2041
Cato Corp
CATO
$67.9M
| $2.8M | ﹤0.01% |
93,200
-98,750
| -51% | -$3.04M |
|
|
NVLN
2042
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $2.8M | ﹤0.01% |
+332,870
| New | +$2.95M |
|
2043
Acme United Corp
ACU
$232M
| $2.8M | ﹤0.01% |
109,600
+2,000
| +2% | +$43.4K |
|
|
EQY
2044
DELISTED
Equity One
EQY
| $2.78M | ﹤0.01% |
+90,500
| New | +$2.65M |
|
|
CHCT
2045
Community Healthcare Trust
CHCT
$432M
| $2.76M | ﹤0.01% |
120,000
-31,200
| -21% | -$697K |
|
|
EFC
2046
Ellington Financial
EFC
$1.76B
| $2.76M | ﹤0.01% |
177,962
+33,613
| +23% | +$537K |
|
2047
Triumph Financial Inc
TFIN
$1.87B
| $2.76M | ﹤0.01% |
105,400
+59,100
| +128% | +$1.26M |
|
2048
IRIDEX
IRIX
$14.9M
| $2.75M | ﹤0.01% |
195,900
-14,600
| -7% | -$207K |
|
|
OXFD
2049
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $2.75M | ﹤0.01% |
183,700
-15,500
| -8% | -$218K |
|
2050
Ryman Hospitality Properties
RHP
$7.92B
| $2.74M | ﹤0.01% |
43,541
+13,041
| +43% | +$723K |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.